Ustekinumab for the Treatment of Giant Cell Arteritis

Objective To evaluate the efficacy and safety of ustekinumab (UST) in giant cell arteritis (GCA). Methods We conducted a prospective, open‐label trial of UST in patients with active new‐onset or relapsing GCA. Active disease was defined as the presence of GCA symptoms and elevation of erythrocyte sedimentation rate (ESR) or C‐reactive protein (CRP) level within 6 weeks of baseline. All patients received a 24‐week prednisone taper and...